The Serendipitous Story of SGLT 2 Inhibitors in Heart Failure : New Insights from DECLARE-TIMI 58 Running

[1]  B. Zinman,et al.  Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. , 2019, Journal of the American College of Cardiology.

[2]  Akshay S. Desai,et al.  Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. , 2019, Circulation.

[3]  B. Akıncı.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. , 2019, The New England journal of medicine.

[4]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. , 2019, Circulation.

[5]  P. Jüni,et al.  Pump, pipes, and filter: do SGLT2 inhibitors cover it all? , 2019, The Lancet.

[6]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[7]  Deepak L. Bhatt,et al.  Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke: Post Hoc Analysis From the LEADER Trial , 2018, Circulation.

[8]  S. Verma,et al.  Empagliflozin Increases Cardiac Energy Production in Diabetes , 2018, JACC. Basic to translational science.

[9]  J. McMurray,et al.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.

[10]  J. McMurray,et al.  Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction , 2018, Diabetes Care.

[11]  G. Filippatos,et al.  Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.

[12]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[13]  A. Tsapas,et al.  Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes , 2015 .

[14]  M. Pfeffer,et al.  Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. , 2014, The lancet. Diabetes & endocrinology.